Kissei Pharmaceutical

Kissei Pharmaceutical, based in Matsumoto, Nagano Prefecture, Japan, develops, manufactures, and sells innovative pharmaceutical products primarily focused on urology, nephrology/dialysis, and rare diseases. The publicly traded company generates annual revenue of approximately $476.1 million and employs between 1,388 and 1,778 individuals. Beyond pharmaceuticals for conditions like type 2 diabetes and allergic diseases, Kissei also produces therapeutic food products for patients with dietary restrictions. Key leadership includes Chairman & CEO Mutsuo Kanzawa and President & COO Yoshio Furihata, with past collaborations including a licensing agreement with GlaxoSmithKline and sales via Choongwae Pharma in South Korea. The organization was founded in August 1946 as Tachibana Seikagaku Institute Co., Ltd. Its business model centers on publicly traded company generating revenue through R&D, manufacturing, and sales of pharmaceuticals and related foods.